Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of compound ad-35 in the treatment of diseases related to gastrointestinal motility disorders

A technology of gastrointestinal peristalsis and compounds, applied in the field of medicine, can solve problems such as strong side effects

Active Publication Date: 2022-04-05
ZHEJIANG HISUN PHARMA CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, currently clinically used acetylcholinesterase inhibitor drugs for the treatment of Alzheimer's disease, such as donepezil, tacrine, rivastigmine, and galantamine, have not been used to treat gastrointestinal motility disorders Any disease associated, including functional dyspepsia (FD), as these acetylcholinesterase inhibitors have strong side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of compound ad-35 in the treatment of diseases related to gastrointestinal motility disorders
  • Application of compound ad-35 in the treatment of diseases related to gastrointestinal motility disorders
  • Application of compound ad-35 in the treatment of diseases related to gastrointestinal motility disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1: Improvement effect of compound AD-35 on delayed gastric emptying in mice induced by clonidine

[0023] ICR mice were randomly divided into groups according to body weight, and fasted for 24 hours. After 55 minutes of administration of the drug group (the model group and the blank control group were given normal saline), the model-making agent clonidine (0.1 mg / kg) was subcutaneously injected into the test animals, and phenol red solution (0.4 ml / only) was administered by intragastric administration 5 minutes later. , and the mice were sacrificed after 30 min. Take out the stomach and place it in 10ml of 0.1M NaOH solution, cut the stomach tissue with scissors to release the stomach contents, centrifuge at 5000rpm for 10min, take 1ml of supernatant, add 0.1ml of 20% trichloroacetic acid to it, and centrifuge at 5000rpm for 20min , take 0.5ml of supernatant, add 0.2ml of 0.5M NaOH solution into it, mix thoroughly, then take the supernatant to detect the OD val...

Embodiment 2

[0024] Example 2 Compound AD-35 improves the delayed gastric emptying induced by clonidine

[0025] SD rats were randomly divided into groups according to body weight, and fasted for 24 hours. After 55 minutes of drug group administration (the model group and the blank control group were given normal saline), the model-making agent clonidine (0.2 mg / kg) was subcutaneously injected into the experimental animals, and phenol red solution (1.6 ml / only) was administered by intragastric administration 5 minutes later. , and the rats were killed by cervical dislocation after 30 min. Take out the stomach and place it in 50ml of 0.1M NaOH solution, cut the stomach tissue with scissors to release the stomach contents, centrifuge at 5000rpm for 10min, take 1ml of supernatant, add 0.1ml of 20% trichloroacetic acid to it, and then centrifuge at 5000rpm for 20min , take 0.5ml of supernatant, add 0.2ml of 0.5M NaOH solution into it, mix well, take the supernatant and detect the OD value at ...

Embodiment 3

[0026] Example 3 Compound AD-35 improves the delay of loperamide-induced intestinal propulsion in mice

[0027] ICR mice were subcutaneously injected with loperamide (5 mg / kg), once a day, for 7 consecutive days to establish models. On the seventh day, a plastic ball with a diameter of 3 mm was pushed 3 cm into the rectum of the mouse, and the time for the plastic ball to be discharged from the rectum was observed and recorded. The mice were randomly divided into groups according to the time when the plastic ball was discharged from the rectum, and different doses of AD-35 were administered to the mice in different administration groups on the second day after grouping (denoted as day1). The mice in each administration group were continuously given different doses of AD-35 on day 1-day 6 (the model group and the normal control group were given normal saline), and then injected loperamide (5 mg / kg) 30 minutes later; after fasting for 4 hours on day 7, Different doses of AD-35 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides the application of the benzodioxole derivative (AD‑35) represented by formula (I) and its pharmaceutical composition in the treatment of diseases related to gastrointestinal motility disorder.

Description

technical field [0001] The invention relates to the field of medicine, in particular to compound AD-35 and its pharmaceutical composition which can be used to treat diseases related to gastrointestinal motility disorder. Background technique [0002] Motility of the gastrointestinal tract is a complex, highly coordinated neuromuscular activity controlled by the autonomic nervous system, hormones, and higher central nervous systems. The clinical manifestations of gastrointestinal motility disorders are dyspepsia symptoms such as easy satiety, abdominal distension, nausea, and vomiting, and can cause gastric and esophageal reflux, leading to esophageal ulcers, and severe cases can be life-threatening. Drugs clinically used to promote gastrointestinal motility mainly include DA receptor antagonists such as domperidone, 5-HT4 receptor agonists such as mosapride, and motilin receptor agonists such as erythromycin. Although these drugs have a certain prokinetic effect, the low sy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4439A61P1/00A61P1/04A61P1/14
CPCA61K31/4439A61P1/00A61P1/04A61P1/14A61K31/454A61K31/4545
Inventor 赵旭阳白骅刘礼飞冯仁田龚永祥李译陈文李琪
Owner ZHEJIANG HISUN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com